Dr. Reddy’s Laboratories shares rallied strongly on Thursday, climbing 10% in afternoon trade even as the broader market remained weak.
The stock was trading at Rs 1,338.70, up Rs 121.70 for the day at around 1:36 pm on the Bombay Stock Exchange (BSE), sharply outperforming benchmark indices that were deep in the red.
The sharp move made Dr. Reddy’s Laboratories one of the top gainers on the Nifty 50 at a time when the Sensex and Nifty were trading sharply lower.
There was no immediate exchange filing or single corporate announcement during market hours that fully explained the sharp jump, suggesting the rally is being driven by a combination of sectoral and stock-specific factors.
The biggest trigger appears to be strong buying in pharmaceutical stocks as investors shifted toward defensive sectors during a risk-off market session.
When markets turn volatile, investors often move money into pharma and healthcare companies because their earnings are generally seen as steadier than cyclical sectors such as autos, metals, IT and financials.
That trend was visible on Thursday, with other pharma names also rallying. Cipla gained more than 4%, while Sun Pharmaceutical Industries was also firmly in the green earlier in the session.
Rising crude oil prices above $100 per barrel and concerns over the economic impact of the West Asia conflict have increased risk aversion in equities, making defensive sectors more attractive.
Among pharma names, Dr. Reddy’s Laboratories is a liquid large-cap stock with strong export exposure, especially to the United States market.
A weaker rupee can also benefit export-oriented drugmakers by improving the value of overseas earnings when converted into rupees.
The stock may also be seeing catch-up buying after recent underperformance. It had closed at Rs 1,217 on Wednesday and remained below its 52-week high of around Rs 1,379 before Thursday’s sharp rebound.
Another possible factor is optimism around its obesity drug opportunity. Business Standard reported that the stock moved close to a brokerage target price and highlighted the company’s early-mover advantage in India’s GLP-1 segment through its DCGI-approved product Obeda.
Traders also said the sharp rise could be getting amplified by short covering, where investors betting on declines rush to close positions as the stock moves higher.
Market participants will watch whether the stock sustains gains above the Rs 1,330 mark through the session.
Investors will also track any exchange filings, analyst commentary, sector momentum and broader market volatility for more clues on the trigger.
If uncertainty remains high in equities, pharma stocks such as Dr. Reddy’s Laboratories could remain in focus as defensive bets.